Phio Pharmaceuticals Corp.

Nasdaq:PHIO

Pharmaceutical Preparations·KING OF PRUSSIA, PA

Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.

CEO

Bitterman Robert J

CFO

Carson Lisa Cabott

All Filings(863 total)

TypeDateAccessionPeriodSize

10-K

Mar 5, 2026

0001437749-26-007078FORM 10-K

Dec 31, 2025

6.2 MB

8-K

Mar 5, 2026

0001437749-26-007071FORM 8-K

Mar 5, 2026

228.8 KB

8-K

Feb 18, 2026

0001437749-26-004542FORM 8-K

Feb 17, 2026

168.2 KB

SCHEDULE 13G/A

Feb 17, 2026

0001649553-26-000030

—

11.5 KB

SCHEDULE 13G/A

Feb 13, 2026

0001213900-26-016522

—

11.4 KB

8-K

Feb 10, 2026

0001437749-26-003575FORM 8-K

Feb 10, 2026

172.2 KB

Feb 6, 2026

0001683168-26-000813

Feb 5, 2026

5.1 KB

Feb 6, 2026

0001683168-26-000811

Feb 5, 2026

5.1 KB

Feb 6, 2026

0001683168-26-000809

Feb 5, 2026

5.0 KB

Feb 6, 2026

0001683168-26-000807

Feb 5, 2026

4.9 KB

Feb 6, 2026

0001683168-26-000805

Feb 5, 2026

5.1 KB

Feb 6, 2026

0001683168-26-000803

Feb 5, 2026

5.0 KB

8-K

Jan 20, 2026

0001437749-26-001500FORM 8-K

Jan 20, 2026

171.9 KB

Jan 2, 2026

0001683168-26-000013

Dec 31, 2025

4.8 KB

Dec 29, 2025

0001683168-25-009349

Dec 23, 2025

4.8 KB

8-K

Dec 23, 2025

0001437749-25-038607FORM 8-K

Dec 23, 2025

166.8 KB

SCHEDULE 13G/A

Dec 11, 2025

0001493152-25-027252

—

7.2 KB

424B3

Dec 4, 2025

0001683168-25-008889FORM 424B3

—

137.2 KB

EFFECT

Dec 3, 2025

9999999995-25-003514

—

1.8 KB

8-K

Nov 25, 2025

0001437749-25-036329FORM 8-K

Nov 25, 2025

173.0 KB

SCHEDULE 13G/A

Nov 24, 2025

0001493152-25-024820

—

7.2 KB

Nov 24, 2025

0001683168-25-008639

Nov 21, 2025

4.8 KB

S-3

Nov 20, 2025

0001683168-25-008586REGISTRATION STATEMENT

—

580.6 KB

Nov 19, 2025

0001683168-25-008537

Nov 18, 2025

4.8 KB

10-Q

Nov 13, 2025

0001437749-25-034857FORM 10-Q

Sep 30, 2025

4.5 MB

25 filings shown